Skip to content
RushPR News – Lifestyle
Author:
Boehringer Ingelheim
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
July 16, 2026
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
July 15, 2026
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
June 22, 2026